The binding sites of the oestrogen receptors α and β have a structural requirement for ligands with two oxygen atoms (one of which is phenolic) spaced 11-12 A / apart. They are open to many non-steroidal compounds, such as those from plants and the chemical industry. The importance of this interaction is the subject of current food safety research. This article examines the methods of assessment of oestrogenicity and their relationship to physiological events.
Introduction
The 20th century saw the development of appreciation and interest in the importance of oes- trogens. They were first isolated in the late 1920s by Butendant [1] and Doisy et al. [2] . By the 1950s, synthetic oestrogens were being used in oral contraceptives. Although it was appreciated that they had a highly selective effect on specific organs (ovaries, uterus and breast), it was not until the pioneering experiments by Jensen et al. [3] in the early 1960s that a biochemical basis for their action was revealed (incidently, an important spin off of the ability to make radioactive compounds). Jensen's discovery of a high-affinity oestrogenbinding protein, albeit in small amounts, which apparently migrated from an extranuclear compartment into the nucleus, also opened the window to the study of other nuclear receptors. It was quickly realized that, prior to its activation by oestrogens, the oestrogen receptor (ER) was part of a larger protein complex [4] . Furthermore, ER and other steroid receptors substantially increased their affinity for binding to DNA following activation by their steroid ligands [5] , thereby providing a rationale for how they could have specific effects on the transcription of genes. This impetus led to the isolation, purification and characterization of receptors for each of the major steroid classes. The subsequent preparation of a set of ER monoclonal antibodies [6] was critical in the cloning of a cDNA encoding human ER [7] . In rapid succession, cDNAs for the other steroid receptors were also isolated [8] [9] [10] [11] . The amino acid sequences of these receptors revealed that they had a common structure with a highly conserved DNA-binding region (90 % homology between each of the receptors), a ligandbinding C-terminal region with intermediate homology, and a low-homology N-terminal region [12] . It was then demonstrated that, once activated, ER disassociates from the heat shock protein Hsp90 [13] and undergoes hyperphosphorylation [14] , thus revealing its DNA-binding domain. This region of ER recognizes short (13-15 bp) palindromic DNA sequences (oestrogen response elements, or EREs) in upstream flanking regions of oestrogen-responsive genes [15] and binds to them as a dimer [16] . The low-homology region was found in the 1990s to contain the transactivation domain where other proteins (co-activators and co-repressors) bind to the transcriptional complex [17, 18] . A greater appreciation of ER interaction with its ligands and the other proteins came from the X-ray crystal structure data [19] .
In 1996, a second, quite distinct ER (as opposed to a single base or deletion mutant) was discovered serendipitously [20] . This form of ER has been named ER ' beta ' (ERβ), thereby leading to the classic receptor being renamed ER ' alpha ' (ERα). ERβ is localized on chromosome 6, whereas ERα is on chromosome 14 [21] . They are differentially expressed in many tissues and within cells in a tissue [21] , particularly with regard to different stages of life [22, 23] . The structure of ERβ has also been determined by X-ray crystallography [24] . Although the amino acid homology of the ligandbinding domain between ERα and ERβ is only 60 %, there are only two differences in the amino acids that make contact with oestrogen ligands in the ligand-binding pocket. This accounts for the similarity in affinities for oestrogens between ERα and ERβ.
Given the knowledge that has been assembled over the past 70 years since the first isolation of steroids, what can we expect next, and what will be the significance of the findings ? The answers to these questions are influenced by other observations that occurred over the same time period. Because of the relatively open nature of the ER-binding pocket, it is quite ' promiscuous ' with respect to the nature of the binding ligand [19, 24] . In general, planar compounds with a phenolic character and two oxygen-containing moieties approximately 11-12 A / (1.1-1.2 nm) apart can fit into the binding pocket. This includes synthetic non-steroidal compounds, such as diethylstilbestrol (' DES ' ; a strong oestrogen), environmental chemicals [e.g. polycyclic aromatic hydrocarbons, 1,1,1-trichloro-2,2-bis-(p-chlorophenyl)ethane(' DDT ')],andpolyphenolsfoundin plants (isoflavones, coumestrol and zearolenones). The apparent decrease in the sperm count that has occurred over the past 50 years [25] has been linked to exposure to these ' oestrogens ', although this has been disputed [26] . This controversy led to support for research in the U.K. However, epidemiological research on the worldwide variation in rates of breast and prostate cancer and cardiovascular disease (the principal causes of death in U.S.A. and Western Europe) revealed that the peoples of southeastern Asia were far less susceptible to these diseases [27, 28] . As the southeastern Asian diet contains substantial quantities of phytoestrogens (mostly the isoflavones in soya), this raised the possibility that the phytoestrogens were in fact providing beneficial effects by protecting against these important chronic diseases [29] . The controversy between adverse and beneficial effects of oestrogen-like substances is providing the impetus to re-examine what we mean by an ' oestrogen ' and whether all oestrogens are equal ?
What is an oestrogen ?
Oestrogens were originally identified by their physiological action on the uterus or other oestrogen-sensitive organs, i.e. they affect growth, differentiation and\or apoptosis. To be of concern to the public in either an adverse or beneficial manner, they must have distinct acute or chronic biological effects. However, as there is a strong interest to rapidly identify the oestrogenic potential of a wide range of substances to which the public is exposed, two types of relatively high throughput screening assays have been used. One is based on how effective an unknown compound is at displacing a true oestrogen (usually tritium-labelled ethinyloestradiol) from an oestrogen receptor [30] . In an analogous, more modern, method, the efficiency of ER binding can also be determined by in silico calculations [31] . However, these methods do not distinguish between oestrogen agonists and antagonists and therefore can only be used to create suspicion, not authentication, of oestrogen action [32] . To try to overcome this limitation, reporter gene assays have been developed. In these, cells (mammalian cells and yeasts) are transfected with an oestrogen receptor cDNA and multiple EREs linked to a reporter gene such as luciferase [33, 34] . In this assay, the putative oestrogen not only has to bind to ER, but now the activated ER has to bind to the ERE and increase the transcription of the luciferase reporter gene. However, although very elegant, this assay may have several limitations. In particular, it fails to take into account the effects of absorption, distribution, metabolism and excretion that fundamentally affect the pharmacokinetics and delivery of the oestrogens and oestrogen-like substances to the target tissue [32] . In addition (but yet to be demonstrated), there is the possibility of differential excretion of the oestrogen-like substance under investigation from these cells (as has been observed for glucocorticoids [35] ).
Delivery of oestrogens to their targets
Physiological oestrogens are released directly into the peripheral blood stream from organs such as the ovary, or are made in situ in individual tissues
Figure 1
Oestrogen metabolism and transport in the small intestine.
Steroidal and non-steroidal oestrogens diffuse into the intestinal cells, where they undergo phase I and phase II reactions. The β-glucuronides (GlcA), phase II metabolites, are pumped back into the lumen by a transporter from the multi-drug resistance (MDR) family. from steroid precursors. Nonetheless, they are rapidly metabolized by both phase I (by oxidation-reduction or hydroxylation) and phase II (glucuronidation and sulphation) reactions. In addition, they bind tightly to plasma proteinsthus only a small proportion (1-2 %) is available to cells. Oestrogens taken orally (either as an oral preparation or in the diet) have a much more difficult route. The small intestine is quite active metabolically and can convert both steroid and non-steroid oestrogens into phase I and phase II metabolites. Recent work has revealed that the β-glucuronides of oestrogen-like polyphenols are actively excreted in a serosal-to-lumen direction [36] , a process governed by a member of the multiple-drug-resistance gene family [36, 37] . This limits the amount of the unconjugated (and hence active) forms of the putative oestrogens that enters the circulation (Figure 1 ). This is not confined to non-physiological oestrogens -a much larger oral dose of 17β-estradiol is needed to give an equivalent uterotrophic effect to an intravenous dose.
In addition to the intestine and the liver, metabolism of oestrogens occurs in several other tissues. In breast, oestrogens are both converted into their sulphate esters by oestrogen and phenol sulphotransferases [38] , and desulphated by sulphatases to their unconjugated forms [39] . The relative contributions of each of these steps vary enormously in tumours. Human ZR-75-1 cells, for instance, overexpress the phenol-sulphating form of phenol sulphotransferase [40] . This makes them impervious to the activity of oestrogenic polyphenols (because of the latter's rapid conversion into their sulphates), but still responsive to oestradiol (a poor substrate for phenol sulphotransferase) [41] .
Putative oestrogens may have other effects that alter oestrogenicity. They may regulate the biosynthesis [42] and metabolism of physiological oestrogens [43] . Thus a dietary oestrogen could have both a direct oestrogenic action on the ER system and an indirect antagonist action as an inhibitor of oestrogen synthesis (e.g., on aromatase) [42] .
Interactions with cellular oxidants
In the case of atherosclerosis, another ' wrinkle ' in metabolism has been postulated. Atherosclerosis is one of several chronic diseases that have an inflammatory component. Neutrophils and macrophages are attracted to the site of the atherosclerotic lesion [44] . There they invade the tissue through the vessel wall and produce proinflammatory oxidants from hydrogen peroxide,
Figure 2
Reaction of tyrosine residues with pro-inflammatory oxidants Macrophages (OH) and ONOO − ), neutrophils (HOCl) and eosinophils (HOBr) produce oxidants that react to form 3-substituted derivatives of tyrosine. Reproduced courtesy of Dorothy Bainton.
such as hydroxyl radical, peroxynitrite and hypochlorous acid [45] [46] [47] . These agents react not only with the lipids and proteins of their intended targets, but also the surrounding tissue, causing collateral damage. Thus the proteins become hydroxylated, nitrated and chlorinated, particularly on tyrosine residues [48, 49] (Figure 2) . As polyphenols have a tyrosine-like, hydroxylated phenyl residue and have had a long history of being anti-inflammatory agents [50] , it was of no surprise that they were shown to react with each of these pro-inflammatory oxidants [51] . Although it seemed that the polyphenols might act as a sink for the pro-inflammatory oxidants, in an alternative hypothesis it has been suggested that the products of reaction between the cellular oxidants and polyphenols might have greater biological effects than the unreacted polyphenols [51] . Preliminary data suggest that chlorination of the isoflavones genistein and daidzein increases their antioxidant properties in a Cu# + oxidation of lowdensity lipoprotein model of lipid peroxidation (B. Boersma, R. Patel, N. Botting, V. Darley-
Figure 3

Gene array classification of different oestrogen classes
It is expected that individual oestrogens will alter the transcription rates of a selected set of oestrogen-responsive genes. By carefully arranging the order in which the genes are laid down on the array, distinct patterns can be perceived. In this example, two house pets are revealed.
Usmar and S. Barnes, unpublished work). These substituent groups may also substantially alter the binding affinity between ERα and ERβ and the phytoestrogens. Indeed, it has been previously argued that iodination of phytoestrogens may increase binding with ERs [52] .
Differential activation of oestrogenresponsive genes
The implicit assumption in evaluation of oestrogenicity is that the putative oestrogen will regulate the same genes as a physiological oestrogen. This is not necessarily true ; indeed, a comparison of the effects of five different oestrogens (oestradiol, nonyl phenol, daidzein, bisphenol A and DDT) on the transcription of six different genes revealed that although all of them down-regulated ER and androgen receptor mRNA, only oestradiol up-regulated progesterone receptor mRNA [53] . The advent of DNA microarray technology on chips will allow a much broader assessment of how individual oestrogens affect transcription of each oestrogen-sensitive gene. Perhaps with careful design of how the genes are placed on the microarray chips, categorizing oestrogens may only require recognition of familiar forms (Figure 3) . Finally, new insights from using proteomics to examine how oestrogens affect protein expression and cycles of protein activation\inactivation will occur.
In summary, in the 21st century we will begin to understand the ways in which oestrogens affect individual biochemical processes in oestrogensensitive cells. In doing so, we will thereby also put into place a more accurate appreciation of the roles of Nature's and man-made alternative oestrogens to our health and disease.
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